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Martin Lukač išin,1 Norbert Goebels,4 Christian Münz,3 Hedda Wardemann,5
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5Max Planck Research Group Molecular Immunology, Max Planck Institute for Infection Biology, Berlin, Germany. 6Department of Pathophysiology,
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The B cell–depleting IgG1 monoclonal antibody rituximab can persistently suppress disease progression in
some patients with autoimmune diseases. However, the mechanism underlying these long-term beneficial
effects has remained unclear. Here, we evaluated Ig gene usage in patients with anti–myelin-associated glycoprotein (anti-MAG) neuropathy, an autoimmune disease of the peripheral nervous system that is mediated by
IgM autoantibodies binding to MAG antigen. Patients with anti-MAG neuropathy showed substantial clonal
expansions of blood IgM memory B cells that recognized MAG antigen. The group of patients showing no
clinical improvement after rituximab therapy were distinguished from clinical responders by a higher load
of clonal IgM memory B cell expansions before and after therapy, by persistence of clonal expansions despite
efficient peripheral B cell depletion, and by a lack of substantial changes in somatic hypermutation frequencies of IgM memory B cells. We infer from these data that the effectiveness of rituximab therapy depends on
efficient depletion of noncirculating B cells and is associated with qualitative immunological changes that
indicate reconfiguration of B cell memory through sustained reduction of autoreactive clonal expansions.
These findings support the continued development of B cell–depleting therapies for autoimmune diseases.
Introduction
Rituximab is a chimeric mouse-human IgG1 monoclonal antibody
that targets the CD20 antigen, which is expressed on immature
and mature B lymphocytes and lost upon plasma cell differentiation (1). The primary mechanism of action of rituximab, at least
early in therapy, is a complete but transient depletion of B cells
through a combination of antibody-dependent cell-mediated
cytotoxicity, complement-dependent cytotoxicity, and direct triggering of apoptosis (2–4). A single course of rituximab leads to
depletion of B cells from peripheral blood for 6–12 months (1).
The FDA has previously approved rituximab for the therapy of
B cell lymphomas, chronic lymphocytic leukemia, and rheumatoid arthritis. More recently, rituximab received FDA approval for
the treatment of patients with granulomatosis with polyangiitis
(Wegener’s granulomatosis) and microscopic polyangiitis. Its offlabel use extends to a broad spectrum of autoimmune diseases,
including systemic lupus erythematosus, idiopathic thrombocytopenic purpura, myasthenia gravis, inflammatory neuropathies,
and multiple sclerosis (1).
The rationale for B cell–depleting therapies in autoimmune diseases has been that immune depletion could eliminate autoreactive B lymphocytes and that de novo regeneration of B cell memory
from pro–B cell precursors — which do not express CD20 — could
reestablish tolerance. However, to our knowledge, no study to
date has demonstrated that B cell–depleting therapies can actuConflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J Clin Invest. 2012;122(4):1393–1402. doi:10.1172/JCI58743.
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ally reconfigure B cell memory through detection of phenotypic or
functional renewal of the B cell repertoire. Thus, despite its clinical
efficacy and widespread use, the mechanisms whereby rituximab
treatment confers its long-term clinical efficacy in patients with
autoimmune diseases are unclear (5).
Anti–myelin-associated glycoprotein (anti-MAG) neuropathy is
a well-defined antibody-mediated disease of the peripheral nervous system that develops in individuals with an IgM monoclonal gammopathy of unknown significance (MGUS) and is characterized by autoreactivity toward MAG, a protein expressed in
the peripheral myelin sheath. IgM anti-MAG antibodies, which
are consistently detectable in these patients, are very likely pathogenic, since their adoptive transfer to susceptible host animals
induces peripheral demyelination and symptoms resembling
those observed in patients with anti-MAG neuropathy (6–9).
Thus, anti-MAG neuropathy stands out among other human
autoimmune diseases due to the known identity of the target
antigen and a clear disease association with IgM autoantibodies. Most available immunomodulatory treatments offer only
transient benefits to some patients with anti-MAG neuropathy,
whereas most remain treatment resistant (10). A recent randomized controlled clinical trial demonstrated that rituximab is, so
far, the most effective therapeutic agent, providing long-term
benefits to a subset of these patients (11). To understand whether these beneficial effects are mediated by lymphodepletion alone
or are sustained by a newly developed peripheral B cell compartment, we examined the Ig gene repertoire in patients with antiMAG neuropathy during rituximab therapy.
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Figure 1
Ig gene repertoire analysis in patients
with anti-MAG neuropathy before and
12 months after rituximab-mediated
B cell depletion. Igh gene variable (V)
region (A), diversity (D) region (B),
and joining (J) region (C) repertoires
in single cell–sorted naive B cells
(CD19+CD27–IgM+), IgM memory B cells
(CD19+CD27+IgM+), and IgG memory B
cells (CD19+CD27+IgG+). Samples were
analyzed before and 12 months after
therapy with rituximab and placebo (normal saline solution). Clonally expanded
sequences were counted as 1 sequence.
Numbers within circles indicate the number of individual sequences analyzed
per patient cohort and time point. Data
for each individual donor are provided in
Supplemental Figures 2–4. The 2-tailed
Fisher exact test was used to evaluate
VH, DH, and JH repertoires.

Results
Ig gene repertoire analysis during therapeutic B cell depletion. To determine whether rituximab-mediated B cell depletion leads to substantial changes in the peripheral Ig gene repertoire, we amplified
and sequenced Ig heavy chain (Igh) genes of single sorted naive B
cells (CD19+CD27–IgM+), IgM memory B cells (CD19+CD27+IgM+),
and IgG memory B cells (CD19+CD27+IgG+) before and 12 months
after therapy. Samples were obtained during a placebo-controlled
clinical trial of rituximab in patients with anti-MAG neuropathy,
during which patients were randomized to 4 weekly infusions of
375 mg/m2 rituximab or normal saline solution as placebo (11).
1394
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The VH, DH, and JH gene family usage before treatment initiation
did not differ between the 2 subgroups (Figure 1) and was similar to demographically matched healthy blood donors (data not
shown). VH3, the largest variable region family, was found most
frequently in any of the B cell subsets, followed by VH4 and VH1. B
cell reconstitution 12 months after rituximab treatment did not
significantly alter the VH, DH, and JH gene repertoire in circulating naive, IgM memory, and IgG memory B cells (Figure 1 and
Supplemental Figures 2–4; supplemental material available online
with this article; doi:10.1172/JCI58743DS1). Next, we examined
Igh characteristics such as the length, charge, and hydrophobicity
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Figure 2
CDR3 length and CDR3 pI before
and after rituximab therapy. The
same number of individual Igh gene
sequences as in Figure 1 were analyzed, and results are displayed
as data derived from individual
sequences. Data points represent
individual sequences; horizontal
bars and error bars indicate mean
± SEM. The unpaired Student’s
t test was used to evaluate CDR3
lengths and pIs.

of the Igh complementarity-determining region 3 (CDR3), which
have previously been associated with antibody-mediated autoreactivity (12, 13). Analysis of a large number of sequences enabled us
to detect small differences such as a modest increase in Igh CDR3
lengths in naive and IgM memory B cells from rituximab-treated
patients, whereas isoelectric points (pIs) remained unchanged after
peripheral B cell reconstitution (Figure 2). We conclude that there
are no consistent abnormalities in the Igh repertoires in patients
with anti-MAG neuropathy and that rituximab-mediated peripheral B cell depletion does not markedly change the VH, DH, and JH
gene family usage of naive and memory B cells.
Size and antigen specificities of IgM memory B cell expansions in antiMAG neuropathy. Patients with anti-MAG neuropathy showed
substantial clonal and oligoclonal expansions within the IgM
memory B cell compartment before treatment initiation: 21.5%
of 809 analyzed single sorted cells had identical Igh CDR3 gene
sequences, compared with 2.3% of 574 sequences derived from
IgG memory B cells (P < 0.0001; Figure 3A). The size of clonal
IgM memory B cell expansions was markedly reduced after rituximab therapy, but not in placebo-treated patients (Figure 3B). We
detected a few expanded clones in the naive compartment: placebo-treated patients showed 0% of a total of 207 sequences before
and 3% of 170 sequences after therapy, compared with 0.3% of 539
sequences before and 1.4% of 353 sequences after therapy in rituximab-treated patients. These expansions — but not nonexpanded
sequences — were somatically hypermutated, which suggests that
these clones represent post–germinal center B cells. In our estimation, the most likely explanation for these few expanded and
somatically hypermutated sequences is the presence of CD27–
memory B cells, which occur at low frequencies in the blood of
healthy individuals and patients with autoimmune diseases (14).
The overall size of these expansions was minimal compared with
the size of expanded sequences within the IgM memory B cell
The Journal of Clinical Investigation

compartment. We observed that the frequency of expanded IgG
memory B cells increased over time in placebo-treated patients.
However, rituximab therapy had no substantial effect on the size
of clonally related IgG memory B cells (data not shown).
To determine whether expanded IgM memory B cell clones
recognize MAG, we re-sorted IgM memory B cells isolated
before treatment initiation and amplified full-length Igh and Ig
light chain variable region gene transcripts derived from highly
expanded sequences by RT-PCR. Amplified products were cloned
into eukaryotic expression vectors to produce monoclonal IgG
antibodies with antigen specificities identical to the initial B cell
antigen receptors (15). The antigenic determinant of MAG resides
in the carbohydrate component of the molecule, as demonstrated by the loss of reactivity following deglycosylation of purified
human MAG (16). A similar carbohydrate structure is found in the
ganglioside fraction of the human peripheral nerve and has been
identified as sulfoglucuronyl glycosphingolipid (SGPG), an acidic
glycolipid exclusively expressed in the peripheral nervous system
(17). Pathogenic IgM antibodies in patients with MAG neuropathy may recognize both MAG and SGPG, although the avidity for
SGPG is reported to be 10- to 100-fold lower than that for MAG
(18). Therefore, we tested both specificities in comparison to an
irrelevant control protein, EBV nuclear antigen 1 (EBNA1) a prominent B cell antigen of the ubiquitous γ-herpesvirus EBV.
All of the 5 clones resurrected from blood IgM memory B cell
expansions before therapy recognized MAG purified from human
myelin in a concentration-dependent manner (Figure 3C).
Of these 5 clones, 1 showed strong cross-reactivity toward
SGPG. Nonexpanded IgM memory clones recognized neither
MAG nor SGPG. Moreover, we did not observe any binding to
EBNA1 (Figure 3C), which indicates that IgM memory B cell
expansions in patients with anti-MAG neuropathy recognize the
target antigen of the disease.
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Figure 3
Size and antigen specificities of clonal IgM memory B cell expansions. (A) Frequency of clonally expanded IgM memory B cells in patients with
anti-MAG neuropathy before and after rituximab therapy compared with the IgG memory compartment. Before therapy, data from all study subjects were included. Post-treatment data refer to those patients that received rituximab therapy. Numbers within circles indicate the number of
individual sequences analyzed per patient cohort and time point. (B) IgM memory B cell clonal expansions before and after therapy in patients
treated with placebo versus rituximab. Results are based on the analysis of individual sequences in both clinical subgroups. The 2-tailed Fisher
exact test was used to compare proportions of clonal expansions. (C) Specificity of IgM memory B cell expansions, as assessed by ELISA.
Recombinant antibodies expressed from highly expanded sequences (see Figure 5B) were tested for binding to purified MAG protein, SGPG,
and EBNA1. Shown are OD values from the positive control (PC) provided by the manufacturer, a secondary antibody control (2°), an antibody
(8-18C5) that recognizes myelin oligodendrocyte glycoprotein (MOG) to control for antigen specificity, and recombinantly expressed antibodies
from patients (P) with anti-MAG neuropathy.

Persistence of clonally expanded IgM memory B cells is associated with
a poor clinical response to rituximab. Next, we determined whether
patients showing a clinical improvement after rituximab treatment (referred to herein as clinical responders; n = 4) could be distinguished from patients with stable or worsened disease (clinical
nonresponders; n = 9) through Igh gene repertoire changes, CDR3
characteristics, and the kinetics of clonal expansions during rituximab treatment. The clinical response was quantified using a
standardized clinical disability scale, and details were previously
reported in the publication of the clinical trial (Table 1 and ref. 11).
Data obtained in clinical responders and nonresponders were
compared with those in placebo-treated patients (n = 6).
VH and DH gene family usage in circulating naive, IgM memory,
and IgG memory B cells before treatment initiation did not differ
between the clinical subgroups, and peripheral B cell reconstitution did not significantly alter the VH and DH gene repertoire 1 year
1396
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after treatment (Supplemental Figures 2 and 3). Before therapy, JH5
usage was more frequently found in the group of clinical responders compared with nonresponders, but these differences lost statistical significance 12 months after rituximab therapy (Supplemental
Figure 4). These data indicate that the clinical response to rituximab therapy is not associated with substantial changes in VH, DH,
and JH gene family usage of naive and memory B cells. The modest increase in CDR3 length after peripheral B cell reconstitution
(Figure 2) could be attributed to clinical nonresponders (Figure 4).
We observed that the group of clinical nonresponders started with
a higher load of IgM memory B cell expansions compared with
responders (P = 0.0043; Figure 5A). Moreover, the reduction of IgM
memory B cell expansions after B cell depletion, as determined by
Igh gene sequence analysis, was less strong in the group of clinical
nonresponders compared with responders (expansions reduced by
factors of 1.3 and 2.7, respectively). Consequently, the amount of

http://www.jci.org

Volume 122

Number 4

April 2012

research article
Table 1
Demographical and clinical characteristics of patients analyzed in
this study
Patient

Clinical
subgroup

Age Sex Disease
(yr)
duration (yr)

INCAT score, leg

P8
P9
P11
P13
P16
P21
P3
P14
P15
P27

Placebo
Placebo
Placebo
Placebo
Placebo
Placebo
Responder
Responder
Responder
Responder

70
56
69
73
68
53
61
72
69
71

M
F
F
F
F
M
M
F
M
M

18
10
21
8
8
7
7
16
9
15

1
1
1
2
3
1
2
2
1
4

1
1
1
2
3
1
1
1
0
1

P5
P6
P10
P12
P17
P18
P22
P23
P26

Nonresponder
Nonresponder
Nonresponder
Nonresponder
Nonresponder
Nonresponder
Nonresponder
Nonresponder
Nonresponder

70
64
73
69
59
76
76
71
47

F
M
M
M
M
M
M
M
M

15
12
9
5
6
13
7
11
6

3
2
1
0
1
1
1
1
1

3
4
1
0
1
1
1
1
1

Baseline 8 months

The primary outcome of the clinical trial was a change of at least 1
point in INCAT disability scale score in the lower extremities at month
8. This validated scale measures leg disability as follows: 0, walking not
affected; 1, walking affected, but walks independently outdoors; 2, uses
unilateral support (cane, single crutch); 3, uses bilateral support (cane,
crutches); 4, uses wheelchair, but able to stand and walk a few steps
with support; 5, restricted to wheelchair. Scoring was done by the same
neurologist for the same patient throughout the study (11).

IgM memory B cell expansions remained increased in clinical nonresponders compared with responders after peripheral B cell reconstitution (P = 0.0041; Figure 5A). Notably, clinical responders that
were included in our study showed a higher then 2-fold decrease in
MAG-specific IgM antibody titers (11), which indicates that inhibition of MAG-specific B cell expansions is associated with inhibition
of pathogenic MAG-specific antibody secretion. However, we did
not detect a significant correlation between MAG titers and the size
of clonal IgM memory expansions in individual patients.
Since the Ig gene repertoire analysis was based on pooled individual sequences, we additionally analyzed the proportions of
clonal expansions per individual patient and compared the mean
proportions between 4 clinical responders and 9 nonresponders. In
line with the analysis based on sequences, clinical nonresponders
tended to start with a higher load of IgM memory B cell expansions compared with responders, and the amount of IgM memory
B cell expansions tended be higher in clinical nonresponders than
in responders after peripheral B cell reconstitution. However, the
statistical significance was lost, possibly as a result of the small sample size (data not shown). Analysis both of pooled sequences and of
sequences per individual patient did not detect any changes in the
Ig gene family usage during rituximab therapy (data not shown).
Continuous as well as categorical outcomes per individual patient
are shown in Supplemental Table 1 and Supplemental Figures 2–4.
The Journal of Clinical Investigation

We identified several identical, expanded IgM memory B cell
clones, which persisted for 12 months in individual placebo-treated patients as well as in clinical nonresponders (Figure 5B). Persisting clonal expansions were not observed in clinical responders
(Figure 5B), which suggests that these persisting expansions may
have contributed to the progression of the disease; however, we
cannot exclude the possibility that persisting, low abundant clonal
expansions would have been detected if a larger number of samples had been analyzed. Frequencies of expanded sequences per
individual patient are listed in Supplemental Table 1. To further
address whether IgM memory B cells in rituximab-treated patients
developed anew or persisted over time, we compared the frequency
of somatic hypermutations (SHMs) in IgM memory B cells before
and after therapy. The degree of SHM was stable in placebo-treated
patients (Figure 6A). Likewise, and despite efficient depletion of
circulating B cells, the overall SHM frequency in circulating IgM
memory B cells remained unchanged in the group of clinical nonresponders (Figure 6A). In contrast, clinically effective rituximab
treatment was associated with a significant reduction in the SHM
frequency in VH of IgM memory B cells (P = 0.0001; Figure 6A).
Notably, the frequency of SHMs in pooled sequences derived from
clinical responders was higher before rituximab therapy, but lower
12 months after, compared with nonresponders (Figure 6B). Mean
SHM frequencies per individual patient also tended to be higher
before but lower 12 months after rituximab therapy in clinical
responders compared with nonresponders; however, statistical
significance was lost, possibly due to the small sample size (data
not shown). The reduction after therapy was strongest in patient
P27, who showed the strongest clinical improvement in response
to rituximab of all clinical responders (Table 1 and Supplemental
Tables 2 and 3). We conclude that clinical nonresponders can be
distinguished from responders with respect to clonal IgM memory
B cell expansion size before and after therapy, persistence of clonal
expansions despite efficient peripheral B cell depletion, and stable
SHM frequencies within the IgM memory compartment.
Discussion
Our study demonstrated that the long-term immunomodulatory
effects of rituximab in anti-MAG neuropathy are mediated by the
sustained reduction of expanded autoreactive IgM memory B cells.
In patients with peripheral nervous system autoimmunity associated with IgM MGUS, which is believed to arise from somatically
hypermutated but non–class-switched B cells that acquire IgM
secretory capacity (19, 20), we showed that IgM memory B cells
contained an important reservoir of autoreactive species, and that
sustained elimination of these cells was associated with clinical
disease remission. Conversely, high load and clonal persistence of
expanded autoreactive IgM memory B cell clones despite efficient
depletion of circulating B cells were associated with a poor clinical
response to rituximab.
Previous studies demonstrated expansion and persistence of foreign antigen-specific memory B cells following infection and vaccination (21–23) and of candidate pathogenic T cell clones in human
autoimmune diseases, such as multiple sclerosis and type 1 diabetes (24–26). The known identity of the target antigen allowed us to
address the dynamic behavior of expanded autoreactive B cells in
patients with anti-MAG neuropathy. The presence of oligoclonal
expansions within the IgM memory B cell compartment before treatment initiation, their ability to recognize MAG protein, and their
persistence in patients with stable or worsened disease suggest that
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Figure 4
CDR3 length and pI before and
after rituximab therapy in clinical
responders and nonresponders.
Patients showing a clinical improvement after rituximab therapy were
classified as clinical responders;
patients with stable or worsened
disease severity were classified as
clinical nonresponders. The same
number of individual Igh gene
sequences derived from rituximabtreated patients as in Figure 2 were
analyzed; results are displayed as
pooled data derived from individual
sequences. Data points represent
individual sequences; horizontal bars and error bars indicate
mean ± SEM. The unpaired Student’s t test was used to evaluate
Igh characteristics.

these persisting expansions may have contributed to disease progression and argue for an important role of MAG-specific IgM memory B
cells in the pathogenesis of this inflammatory neuropathy.
Clinical responders showed qualitative immunological changes
that indicated reconfiguration of B cell memory through sustained
reduction of autoreactive expansions and changes in SHM frequencies. While these changes might be driven by different cellular subsets that contributed to the CD27+IgM+ B cell pool in both clinical
subgroups, they indicate that the IgM memory compartment in
clinical responders was repopulated by newly developed B cells. In
contrast, based on the lack of significant changes in SHM frequencies, we found no evidence for a substantial de novo generation of
IgM memory B cells in clinical nonresponders, which suggests that
at least a fraction of disease-relevant B cells are not accessible for
or susceptible to CD20 immunotherapy. In patients with rheumatoid arthritis, the depleting effect of rituximab was reported to be
more profound in the peripheral blood than in inflamed joints or
bone marrow (27–29). Although the clinical response status was
not addressed in the prior studies, the results obtained here suggest that targeting of B cell–depleting antibodies to professional
lymphoid tissues and sites of autoimmune inflammation for the
sustained elimination of autoreactive B cells might increase the
clinical efficacy of CD20 immunotherapy.
Rituximab was evaluated for its clinical efficacy in anti-MAG
neuropathy based on its potential to reduce pathogenic IgM antibodies by depleting B cells. Initial uncontrolled phase II studies
reported that some patients show clinical improvement following rituximab therapy (30–32). Patients who initially responded
well to rituximab in one of the aforementioned clinical trials were
prospectively observed without treatment for another 36 months.
Despite the reappearance of circulating B cells, a sustained clinical benefit after a single rituximab course was noted that lasted
up to 24 months in 80% of patients and up to 36 months in 60%
of patients (33). Disease recurrence was best correlated with high
1398
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baseline anti-MAG titers and increasing anti-MAG antibodies at
follow-up, and the authors suggested that patients with high antiMAG titers may require additional courses with rituximab (33).
In a small series of 8 patients, administration of a double dose of
rituximab (750 mg/m² every week for 1 month) 17–27 months
after standard dose treatment (375 mg/m²) improved the clinical
outcome. High-dose treatment was also efficient in inducing a
first clinical response associated with reduced anti-MAG antibody
titers in patients that were refractory to the standard treatment
(31). We found that a high load of oligoclonal B cell expansions
before therapy and low efficiency to reduce B cell expansions with
rituximab was associated with a poor clinical response. The small
sample size of our study and the pooled analysis did not allow
us to address whether the size or reduction of oligoclonal expansions is a biomarker for the clinical response to rituximab in individual patients. Such analyses require larger study populations
and confirmation in independent cohorts. Our data, however,
suggest that patients who show no clinical improvement after a
first round of rituximab therapy could benefit from additional
treatment rounds to deplete or further reduce the frequency of
clonally related autoreactive B cells.
In conclusion, our data indicate that the therapeutic efficacy of
rituximab in anti-MAG neuropathy depends on efficient depletion
of noncirculating B cells and is associated with qualitative immunological changes that indicate reconfiguration of B cell memory.
These findings provide a mechanistic basis for the differential clinical response to rituximab in anti-MAG neuropathy and support
the therapeutic concept of ongoing and future clinical trials of B
cell–depleting therapies in autoimmune diseases.
Methods
Patients. We analyzed specimens from patients that were included in a double-blind, placebo-controlled study of rituximab in patients with anti-MAG
demyelinating polyneuropathy that was carried out at the NIH (Table 1

http://www.jci.org

Volume 122

Number 4

April 2012

research article

Figure 5
Higher load of IgM memory B cell expansions and persistence of expanded IgM memory B cells is associated with a poor clinical response to
rituximab. (A) IgM memory expansions before and after rituximab therapy in pooled samples from clinical responders and nonresponders. Results
are based on the analysis of individual sequences in both clinical subgroups. Numbers within circles indicate the number of individual sequences
analyzed per patient cohort and time point. The 2-tailed Fisher exact test was used to compare proportions of clonal expansions. (B) IgM memory B cell expansions in individual clinical responders or nonresponders compared with placebo-treated patients. Gray shading, nonexpanded
sequences; differently colored shading, clonally expanded CDR3 sequences; black shading, sequences detected before and after therapy in individual patients are highlighted in black. Circles denote expanded sequences that were resurrected as IgG monoclonal antibodies (see Figure 3B).
Due to the low frequency of memory B cells in 2 post-treatment samples, we were not able to amplify PCR products (ND, not determined).

and ref. 11). Patients were selected if they had clinical and electrophysiological evidence of a demyelinating neuropathy, a benign IgM monoclonal spike, and anti-MAG antibodies. Patients did not receive any immunosuppressive therapy for at least 6 months before enrollment. At entry,
all patients (except 1) had impaired function, as evidenced by affected balance and/or coordination, frequent falls, or muscle weakness, reflected in
an Inflammatory Neuropathy Course and Treatment (INCAT) disability
score of at least 1 (see Table 1). The study was conducted at the NIH under
a Cooperative Research and Development Agreement between National
Institute of Neurological Disorders and Stroke and Genetech. The trial was
registered at ClinicalTrials.gov (NCT00050245) and was conducted under
a protocol approved by the National Institute of Neurological Disorders
and Stroke institutional review board. After randomization, 4 weekly intravenous cycles of 375 mg/m2 rituximab or placebo (consisting of a normal
The Journal of Clinical Investigation

saline solution) were administered. Patients were premedicated with acetaminophen (650 mg) and diphenhydramine (25 mg) before infusions. The
primary outcome was a change of at least 1 point in INCAT disability scale
score in the lower extremities at month 8. This is a validated scale previously used in inflammatory demyelinating neuropathies, including the
IgM anti-MAG neuropathy (11, 34, 35). The 4 patients that improved by at
least 1 INCAT point after 8 months were classified as clinical responders;
the other patients with stable or worsened disease were classified as clinical nonresponders. Individual demographical and clinical profiles of all
patients included in this study are given in Supplemental Table 1.
Flow cytometry and single cell analysis. Frozen PBMCs were thawed in FACS
buffer (2 mM EDTA, 5% FCS, 20 μg/ml DNAse [Roche] in PBS). After
thawing, the PBMCs were strained (0.22-μm cell strainer; BD) and centrifuged for 15 minutes at 150 g and 4°C. The cells were incubated with
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Figure 6
Lack of change in SHM frequencies in IgM memory B cells is associated with a poor clinical response to rituximab. (A) Mean SHM frequencies of
IgM memory B cells in framework and CDR regions (FWR1, CDR1, FWR2, CDR2, and FWR3) in placebo-treated patients and in clinical responders and nonresponders before and after rituximab therapy. (B) Mean SHM frequencies before and after rituximab therapy in clinical responders
versus nonresponders. Expanded sequences were taken into account only once in order to analyze SHM frequencies in IgM memory B cells
independent from clonal expansions. Results are based on the analysis of individual sequences in clinical subgroups. The unpaired Student’s t
test was used to compare SHM frequencies.

PE-conjugated anti-CD27 clone M-T271, PE-Cy7–conjugated anti-CD19
clone SJ25C1, allophycocyanin-conjugated anti-IgM clone G20-127, biotin-conjugated anti-IgG clone G18-145, and FITC-conjugated streptavidin
(all BD) and with component H (Invitrogen) for dead cell discrimination.
Single CD19+CD27–IgM+ naive B cells, CD19+CD27+IgM+ memory B cells,
and CD19+CD27+IgG+ memory B cells were purified by flow cytometric
cell sorting using a Facs Aria machine and Diva software (both BD). The
gating strategy is depicted in Supplemental Figure 1. Single cell sorting
was directly into a 96-well plate (thermoquick PCR-Plate; Greiner bioOne)
with 20 μl reverse transcription buffer or Qiagen OneStep RT-PCR reaction mix (Qiagen) supplemented with 0.5 μM each of Igh variable region–
specific forward and IgG/IgM reverse primers per well (15). Directly after
sorting, buffer plates were frozen on dry ice, and Qiagen OneStep RT-PCR
plates were incubated for 60 minutes at 50°C for reverse transcription.
After the reverse transcription step, DNA polymerase was activated with
an initial step of 15 minutes at 95°C. Amplification of the resulting cDNA
of Igh was performed at an annealing temperature of 58°C for 45 seconds,
an elongation temperature of 72°C for 1 minute, and a denaturation temperature of 94°C for 30 seconds for 48 cycles. Nontemplate controls were
included to exclude contaminations in the master mix.
To reduce PCR error rates, we used the HotStar Taq DNA polymerase
(Qiagen) with an error rate of 2 × 10–5 per nucleotide and cycle. PCR amplicons were separated by electrophoresis on a 1.2% agarose gel. To avoid
1400
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cross contaminations on the gel, PCR products were physically separated
from each other. Bands with the correct mass (approximately 500 bp) were
excised using individual sterile scalpels; DNA was extracted (Qiagen MiniElute Gel Extraction Kit) and sequenced. The sequenced variable region
of the amplified Igh was corrected with CLC Main Workbench and analyzed on the international immunogenetic information system (36, 37).
The variable region was analyzed for VH, DH, and JH usage; SHMs; CDR3
length; pI; and clonal expansion.
Sequence analysis. After blasting, the sequences’ clonal expansions were
determined by similar CDR3 aa sequences and V H, D H, and J H usage.
The length of the CDR3 was defined as the number of aas from the
third position after the cysteine motive of the CDR3 to the tryptophan
aa. For pI analysis, we used the entire aa sequence of the CDR3 and
calculated it with the tool on ExPASy proteomics server (ref. 38 and
Figures 2 and 4). The VH, DH, and JH gene usage was weight balanced by
the number of sequences derived from each donor to avoid tempering
the result by different amount of sequences due to clonal expansion or
PCR efficacy. For the SHM analysis, sequences were first blasted against
the germline sequences in the database of IMGT. The blast result of
unique IgM memory B cells in framework and CDR regions was used
to calculate percent bp exchange by dividing the number of mutations
by the length (in bp) of the individual variable region elements (FWR1,
CDR1, FWR2, CDR2, and FWR3).
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Expression vector cloning. Expanded sequences were reconfirmed via an
additional PCR from the presorted 20-μl reverse transcription buffer plate.
The corresponding Ig light chain was used to rule out contaminations and
the cloning of the antibodies. For this purpose, RNA of the single frozen
cell was divided into 3 RT-PCRs: 1 for Igh and 2 for Ig light chain (λ and κ;
Igl and Igk, respectively). The recovered Igh sequences were then compared
with the previous sequences. The corresponding Igh and Igk or Igl genes
were cloned into expression vectors as previously described (15). The
recombinant monoclonal antibodies were expressed in 293T cells after calcium phosphate–mediated transfection with 22.5 μg of each vector DNA
(Igh and Igl). After 3 days, antibodies were purified from cell culture supernatants over a protein G column. The elution was performed with 0.1 M
glycine (pH 2) and dialyzed overnight in PBS (pH 7.4).
ELISA. Specificities of recombinant antibodies were evaluated at different concentrations (0.001, 0.005, 0.01, 1, 10, and 50 μg/ml) using 3 commercially available ELISA kits (anti-SPGP ELISA kit, anti-MAG ELISA kit,
both Bühlmann Laboratories; EBNA1 IgG ELISA, Bio-Rad). The ELISAs
were performed according to the manufacturers’ recommendations. The
OD signal obtained with the negative control provided by the manufacturer was subtracted from the OD signals of experimental samples. To
detect the recombinantly expressed IgG molecules, a goat anti-human
IgG secondary antibody coupled to HRP was used in the MAG and SGPG
ELISA (Sigma-Aldrich). The detection was done with TMB substrate that
was stopped with 1M H2SO4, and absorbance was measured at 450 nm.
Statistics. Unpaired Student’s t test (2-tailed) was used to compare CDR3
length, pI, length of DH and N elements, and SHM frequencies before and
after rituximab treatment. The 2-tailed Fisher exact test was used to compare frequencies of VH gene family usage and the size of clonal expansions.
All analyses are based on individual sequences, and data in figures in which
error bars are shown are presented as mean ± SEM. Since we analyzed
pooled sequence data, a repeated-observation analysis was not applied. A
P value less than 0.05 was considered significant.
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